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ditorialshere  is  the  focus  on  hepatitis  C  research  after  the  introduction  of
AAs:  To  Understand,  knowledge,  prevent  or  cure  hepatitis  C?The interests and approaches in science are very changing,
nd it is not uncommon to obey economic and political purposes
f pharmaceutical companies and governments in turn. Perhaps
ue to the lack of sufficient public resources, in several countries
uch as our, priority funding in science and technology is articu-
ated for research programs that allow finding interdisciplinary and
ransversal solutions to the great national problems, thus estab-
ishing National Strategic Programs.1 These types of initiatives
re adequate; however, the generation of basic science is lagging
ehind, which also generates knowledge applicable in the longer
erm. The interests in generating frontier science have changed dra-
atically in recent years, which have greatly modified the approach
nd the different routes in the understanding of human diseases. In
he area of hepatology, the generation of scientific knowledge is an
ncubation process that must be taken care of from a long-term per-
pective, starting from the understanding of molecular processes
o design new drugs that improve or restore liver function.2,3 In
his editorial, we highlight the need to continue supporting the
eneration of basic scientific knowledge in hepatology, that later
n in conjunction with clinical research, will allow us to establish
ranslational medicine to create preventive strategies, new treat-
ents, vaccines and new antivirals to combat viral hepatitis and
emonstrate how basic scientific knowledge is applied to patient
are.
In recent years, our knowledge about the hepatitis C virus (HCV)
as expanded. Numerous aspects of the virus replication cycle have
een published, as well as abundant knowledge generated about
he molecular mechanisms of pathogenicity of this virus. All this
valanche of knowledge has allowed the development of currently,
ffective antiviral treatments. Particularly, in the case of hepatitis
, since the launch in 2011 of the first specific direct-acting antivi-
al agents (DAAs) that demonstrated to reduce viral load (reaching
n SVR in more than 90% or 95% of the patients who  received
reatment) directly affecting a viral target, the investigation in hep-
titis C has dramatically turned in this direction towards the search
or new specific antivirals, as well as the corresponding clinical
rial with all its preclinical and clinical stages. Nowadays, there
re several options accessible for HCV treatment, such as DAAs,
ncluding HCV protease inhibitors, polymerase inhibitors, and NS5A
nhibitors. As spectators of the field, it seems that the search for a
accine against this virus that allows prophylactically combating
he spread of this disease has been left aside in an important way.
ikewise, it seems that the same thing happens in the processes or
ttps://doi.org/10.1016/j.aohep.2020.02.002
665-2681/© 2020 Fundación Clı́nica Médica Sur, A.C. Published by Elsevier España
reativecommons.org/licenses/by-nc-nd/4.0/).regulations to combat the transmission of the disease through one
of its main old routes, such as blood transfusion and blood prod-
ucts. Under this same wording it is important to highlight that in
many blood banks, the identification of blood donors infected with
the hepatitis C virus is only carried out by ELISA and western blot
tests, and the use of nucleic acid tests (NAT) has not been general-
ized in order to establish a more accurate and reliable diagnosis and
prevent transmission during the immunological window period.
Nowadays the funding for basic research started to be consid-
ered of little relevance in our country, and it is actually imperative
that HCV research needs to be evaluated in order to establish priori-
ties to fulfill the goal of eradication in the upcoming years. We  need
to focus in the detection of those clinically silent HCV infections,
developing cheaper drugs and therapies for those who  do not have
access to the current DAAs, new vaccine development technologies,
face antiviral resistance, and the risk of developing hepatocellular
carcinoma (HCC) after antiviral treatment and viral clearance. It
is important to highlight that recently it has been reported that
CHC appears shortly after HCV clearance with antivirals, that is,
less than 10 years, especially in patients with advanced fibrosis
or cirrhosis and it seems to be more common in genotypes other
than the common ones, so it should be investigated. 4–6 In addi-
tion, nowadays the gap between basic and clinical research has
been reduced with the raise of translational science funds, which
facilitates the interaction among clinicians, scientists, academia,
industry and governments. In this regard, an example of this is in
genomic medicine research which looks for strategies to prevent
liver disease progression.7
We know that HCV is capable of evade the immune system
response and one of the barriers in the development of a vaccine
is the lack of an immune-competent model where the virus could
replicate and the immune response could be evaluated. With the
DAAs based therapy, the possibility to study the immune reconsti-
tution in patients undergoing DAA-based therapy and eliminating
the virus is an opportunity to starting to cover the lack of informa-
tion in this regard. The Norway rat hepacivirus, recently discovered,
can be propagated in lab strains of mice and it seems to have some
of the immunological features that HCV has, and that is important
to promote the vaccine development.8,9Regarding research priorities in this field, much remains to be
understood about the molecular mechanisms of HCV pathogenic-
ity. This will allow us not only to design new antiviral drugs, but also
to look for new ways that facilitate the regression of damage and
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estoration of functionality in the infected and cleared HCV liver.
ne of the most important areas to continue generating knowledge
hat allows not only eradicating the virus but also recovering liver
unction is to understand the mechanisms involved in liver damage
esolution upon hepatitis C virus clearance. Once the virus is elim-
nated patients should try to re-establish their metabolic functions
fficiently from an environment where there was  great cellular
estruction. Once the causative agent of damage is removed, the
rogression of liver disease is attenuated.
However, if the patient has an advanced state of fibrosis or cir-
hosis, hepatic regeneration becomes a challenge where numerous
nown and unknown cellular mechanisms are involved. Fortu-
ately, there are drugs that facilitate this process of reversion;
owever, it is still not clear what conditions favor the success of
his regression. From this perspective, the participation of several
ubcellular compartments in the cytoplasm has taken great impor-
ance, such as the endoplasmic reticulum and mitochondria. The
ndoplasmic reticulum (ER) is the major cell site to achieve protein
olding and calcium storage. In addition ER regulates cholesterol
roduction and lipid-membrane biosynthesis as well as major sur-
iving and cell death pathways. Alteration of ER function induces
dverse effects in liver function, as reported in fibrosis, cirrhosis
nd hepatocellular carcinoma. On the other hand, this organelle is
ntimately linked to the function of the mitochondria. Mitochon-
ria has a critical role in generation of cellular energy (as ATP),
alcium and redox homeostasis, surviving cellular signaling and
ell death. ER and mitochondria share the protective mechanisms
o restore their damaged function by known intrinsic and extrin-
ic stresses, but heir chronic dysfunctions are associated with viral
athogenesis
Our research during the past 25 years has focused in the molec-
lar mechanisms of HCV pathogenicity, and more recently about
he study of antioxidant molecules with promising antiviral action.
uch is the case of acetyl salicylic acid and gallic acid, both with
ntioxidant capacities and with prominent antiviral effect against
CV.10,11
Studies of the HCV replication cycle and virus-host interaction
ave provided important insights that helped to develop the direct
ntiviral therapy available nowadays. For example, HCV-related
tudies have directed research on interferon lambda, an important
ntiviral cytokine discovered only more recently.12 Additionally,
e recently reported the role of s-adenosyl methionine (SAM) in
CV downregulation.13 SAM is the main precursor of glutathione
ynthesis and also is considered the principal methyl donor.14 We
eported that this molecule regulates the expression of interferon
amma  mRNA, which is related to antiviral effect against HCV.
ecently there has been reported that APOE ε4 allele and LDL-
holesterol level confer a protective effect in the course of the HCV
nfection in the context of high BMI, this suggests that hostś, envi-
onmental and metabolic factors should be taken into account to
ive a personalized therapy and also these factors could be used to
arly detection of chronicity in HCV-infected patients.15
Understanding how HCV modulates cell signaling pathways will
llow us better therapeutic approaches to once the virus has been
radicated; start new therapies that facilitate the improvement
f liver function. As a last point to reflect, worldwide the dis-
osition of antivirals does not reach us all equally. Mexico is far
rom reaching the eradication of viral hepatitis. Antivirals are stillgy 19 (2020) 119–120
expensive and therefore more accessible treatment strategies must
be established for the Mexican and Latin American patient. All these
elements together must be considered to comprehensively address
the understanding, prevention, cure and restoration of liver func-
tion after HCV infection.
References
1 Martínez López, Cornelio García Pérez MA.  Reforma al Conacyt y al Sistema
Nacional de Ciencia, Tecnología e Innovación, en la LXIV Legislatura. Mirada
Legis. 168:17.
2  Panduro A. The Editorial Challenges Faced by International Medical Journals in
Latin America. Ann Hepatol 2018;17(5):749–51.
3 Panduro A, Roman S. Need of righteous attitudes towards eradication of hepati-
tis C virus infection in Latin America. World J Gastroenterol 2016;14:5137–42.
4 Baumert T, Juhling F, Ono A, Hoshida Y. Hepatitis C-related hepatocellular car-
cinoma in the era of new generation antivirals. BMC  Med  2017;15:52.
5 Kanwal F, Kramer J, Asch S, Chayanupatkul M,  Cao Y, El-Serag H. Risk of hep-
atocellular cancer in HCV patients treated with direct-acting antiviral agents.
Gastroenterology 2017;153:996–1005.
6 Rinaldi L, Perrella A, Guarino M,  De Luca M,  Piai G, Coppola N, et al. Incidence and
risk factors of early HCC occurrence in HCV patients treated with direct acting
antivirals: A prospective multicentre study. J Transl Med  [Internet]. BioMed
Central; 2019;17(1):1–10. Available from: https://doi.org/10.1186/s12967-
019-2033-x.
7 Panduro A, Tiribelli C, Chávez-Tapia NC, Arrese M,  Uribe M.  Renovation of annals
of  hepatology’s scientific scope: Towards preventing rather than treating end-
stage liver disease. Ann Hepatol 2018;17(4):539–40.
8 Trivedi S, Murthy S, Sharma H, Hartlage A, Kumar A, Gadi S, et al. Viral per-
sistence, liver disease and host response in Hepatitis C-like virus rat model.
Hepatology 2017.
9 Billerbeck E, Wolfisberg R, Fahnoe U, Xiao J, Quirk C, Luna J, et al. Mouse models
of  acute and chronic hepacivirus infection. Science (80-) 2017;357:204–8.
10 Trujillo Murillo K, Rincón Sánchez AR, Martínez Rodríguez H, Bosques Padilla
F,  Ramos Jiménez J, Barrera Saldaña HA, et al. Acetylsalicylic acid inhibits hep-
atitis C virus RNA and protein expression through cyclooxygenase 2 signaling
pathways. Hepatology 2008;47(5):1462–72.
11 Govea Salas M,  Rivas Estilla AM,  Rodriguez Herrera R, Lozano Sepúlveda
S,  Aguilar Gonzalez C, Zugasti Cruz A, et al. Gallic acid decreases hep-
atitis C virus expression through its antioxidant capacity. Exp Ther
Med  [Internet] 2015;11:619–24. Available from: http://www.spandidos-
publications.com/10.3892/etm.2015.2923.
12 Boisvert M,  Shoukry N. Type III interferons in hepatitis C virus infection. Front
Immunol 2016;7:628.
13 Lozano-Sepulveda SA, Bautista-Osorio E, Merino-Mascorro JA, Varela-Rey
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